Work

Supplementary Figure S3 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal

Year: 2025

Type: supplementary-materials

Abstract: Supplementary Figure S3. Mutation prevalence in specified pathways for anal cancer (A);alterations noted in more commonly altered pathways (B).

DOI: 10.1158/1078-0432.28910986

Authors: Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio Wistuba, Arjun Peddireddy, James Yao, Julia Mendoza-Perez, Mark Knafl, Scott E. Woodman, Cathy Eng, Daniel Halperin

Language: English

Topic: Colorectal and Anal Carcinomas

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4410009873

Cites:

Cited by:

Related to: 10